Recha, Erlinda O.

HRN: 22-57-22  Sex: Female

Patient Encounter


AMS Audit List

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
02/03/2023
CLINDAMYCIN 150MG/ML, 4ML (AMP)
02/03/2023
02/09/2023
IV
300mg
Q6
Invasive Ductal Breast CA, Left
Waiting Final Action 
02/03/2023
CEFTRIAXONE 1G (VIAL)
02/03/2023
02/09/2023
IV
2g
OD
Invasive Ductal Breast CA, Left
Waiting Final Action 
02/14/2023
CEFTRIAXONE 1G (VIAL)
02/14/2023
02/23/2023
IV
2g
OD
Invasive Ductal Ca, L Breast
Waiting Final Action 
02/14/2023
CLINDAMYCIN 150MG/ML, 4ML (AMP)
02/14/2023
02/24/2023
IV
300mg
Q6h For 3 More Days
Invasive Ductal Ca, L Breast
Waiting Final Action 
08/19/2023
AMPICILLIN 1GM + SULBACTAM 500MG (VIAL)
08/19/2023
08/25/2023
IV
1.5g
Q6
Soft Tissue Infection
Checking Final Appropriateness 

AMS Audit Form


Start Date: End Date:

 Indication:

              

 Type of Infection:

                             

           

 Compliance to guidelines:



 Initial appropriateness:



 If inappropriate:

           

 Final appropriateness:



 If inappropriate:

              

 Overall appropriateness: